This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View (Revised)
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.
Exelixis (EXEL) Amends Agreement With Iconic Therapeutics
by Zacks Equity Research
Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.
Exelixis (EXEL) Initiates Study on XL092 in Advanced Solid Tumors
by Zacks Equity Research
Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.
Exelixis (EXEL) Down 14.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck's (MRK) Keytruda Gets Approval for Certain RCC Patients
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or following nephrectomy and resection of metastatic lesions.
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
by Zacks Equity Research
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
EXEL vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and revenues in the third quarter. Both figures increase on a year-over-year basis.
Exelixis (EXEL) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of -36.84% and -10.35%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming third-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.
Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.
Is a Surprise Coming for Exelixis (EXEL) This Earnings Season?
by Zacks Equity Research
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?
by Zacks Equity Research
Regeneron's third-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital approach to administering vaccines across the nation is expected to have strongly contributed to its Q3 performance.
Is a Beat in Store for Generac (GNRC) This Earnings Season?
by Zacks Equity Research
Generac's (GNRC) third-quarter 2021 earnings are likely to have been driven by a solid demand environment and effective acquisition strategies supported by a resilient business model.
Is a Beat in Store for T-Mobile (TMUS) This Earnings Season?
by Zacks Equity Research
T-Mobile's (TMUS) performance in the third quarter of 2021 is likely to have benefited from customer growth and 5G network expansion.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) third-quarter earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and pipeline progress.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 52% Upside in Exelixis (EXEL): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.2% in Exelixis (EXEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Buy Stocks for October 26th
by Zacks Equity Research
HCCI, PKX, DFH, EXEL, and FAF have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2021.
Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review
by Zacks Equity Research
Novartis (NVS) reports mixed results in the third quarter, as key brands maintain momentum but generics business remains weak.
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Well Poised on Label Expansions of Caboemtyx
by Zacks Equity Research
The going has been good for Exelixis (EXEL) on label expansions of its lead drug, Cabometyx. The pipeline progress has been encouraging as well.